AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22237311 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-649868 30 mg
Number of subjects: 51
Study 22237311 — intervention group
Group type: COMPARATOR
Intervention: Zolpidem 10 mg
Number of subjects: 51
Study 20072058 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stretching (12 x 15 seconds)
Number of subjects: 150
Study 20072058 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stretching (6 x 30 seconds)
Number of subjects: 150
Study 20072058 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stretching (4 x 45 seconds)
Number of subjects: 150
Study 20072058 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stretching)
Number of subjects: 150
Study 18046055 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk (mixed protein‐carbohydrate)
Number of subjects: 5
Study 18046055 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 5
Study 18046055 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (CHO)
Number of subjects: 5
Study 16124965 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 consecutive days of activity sampling
Number of subjects: 131
Study 16124965 — intervention group
Group type: COMPARATOR
Intervention: 7 or more days of activity sampling
Number of subjects: 131
Study 12183720 — intervention group
Group type: EXPERIMENTAL
Intervention: TUDCA (30 mg/kg/day)
Number of subjects: 52
Study 12183720 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated/placebo)
Number of subjects: 52
Study 10357350 — intervention group
Group type: EXPERIMENTAL
Intervention: Combitube (CT)
Number of subjects: 75
Study 10357350 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal intubation (ET)
Number of subjects: 75
Study 10357350 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 75
Study 8543491 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 500 mg intravenously every 8 h
Number of subjects: 153
Study 8543491 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 250-1000 mg intravenously every 8 h
Number of subjects: 153
Study 8543491 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 2 g every 8 h + amikacin 15 mg/kg/day
Number of subjects: 153
Study 8543491 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 1 g every 8 h
Number of subjects: 153
Study 8543491 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime + amikacin
Number of subjects: 153
Study 8543491 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 153
Study 2394323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramp distention with water
Number of subjects: 12
Study 2394323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramp distention with air
Number of subjects: 12
Study 2394323 — intervention group
Group type: EXPERIMENTAL
Intervention: Low infusion rates
Number of subjects: 12
Study 2394323 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid intermittent distention
Number of subjects: 12
Study 2394323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramp inflation at lower infusion rates
Number of subjects: 12
Study 2394323 — intervention group
Group type: EXPERIMENTAL
Intervention: All circumstances of rectal sensation
Number of subjects: 12
Study 7436164 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated oral charcoal, 6 g daily for 8 weeks
Number of subjects: 11
Study 7436164 — intervention group
Group type: COMPARATOR
Intervention: Placebo dextrose
Number of subjects: 11
Study 31502859 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine (MK‐1439)
Number of subjects: 0
Study 27956164 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 136
Study 27956164 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic surveillance (control)
Number of subjects: 136
Study 25600063 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 96
Study 25600063 — intervention group
Group type: COMPARATOR
Intervention: Dorsal hand vein
Number of subjects: 96
Study 25600063 — intervention group
Group type: COMPARATOR
Intervention: Saphenous vein
Number of subjects: 96
Study 24924991 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented post-remission therapy (regimen C) including additional eight doses of pegylated asparaginase, 18 doses of vincristine, and escalated-dose intravenous methotrexate without folinic acid rescue.
Number of subjects: 533
Study 24924991 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (treatment regimens A and B).
Number of subjects: 533
Study 24924991 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented post-remission therapy (regimen C).
Number of subjects: 533
Study 22982948 — intervention group
Group type: EXPERIMENTAL
Intervention: Park environment
Number of subjects: 40
Study 22982948 — intervention group
Group type: COMPARATOR
Intervention: Urban environment
Number of subjects: 40
Study 22982948 — intervention group
Group type: EXPERIMENTAL
Intervention: Both environments
Number of subjects: 40
Study 19916990 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg once daily for 3 months)
Number of subjects: 50
Study 19916990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 17515510 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.4% retinol lotion
Number of subjects: 36
Study 17515510 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 36
Study 15477633 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg once daily)
Number of subjects: 907
Study 15477633 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (20 mg once daily)
Number of subjects: 907
Study 15477633 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 907
Study 15477633 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 907
Study 11472700 — intervention group
Group type: EXPERIMENTAL
Intervention: RPR 109891 (oral glycoprotein IIb/IIIa antagonist) plus aspirin
Number of subjects: 420
Study 11472700 — intervention group
Group type: EXPERIMENTAL
Intervention: RPR 109891 (oral glycoprotein IIb/IIIa antagonist)
Number of subjects: 420
Study 9551029 — intervention group
Group type: EXPERIMENTAL
Intervention: fluvastatin 60 mg/day
Number of subjects: 0
Study 9551029 — intervention group
Group type: EXPERIMENTAL
Intervention: fenofibrate (micronized) 200 mg/day
Number of subjects: 0
Study 9551029 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin 20 mg/day
Number of subjects: 0
Study 8064370 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet A (12% of total energy as protein)
Number of subjects: 55
Study 8064370 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet B (21% of total energy as protein)
Number of subjects: 55
Study 1776743 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC)
Number of subjects: 0
Study 673095 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide suspension
Number of subjects: 0
Study 673095 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum carbonate powder in capsule form
Number of subjects: 0
Study 673095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31383235 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast and fluticasone (anti-inflammatory treatment) for 12 weeks
Number of subjects: 26
Study 31383235 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 26
Study 28498504 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (2 mg/day, after 1-week dose run-up)
Number of subjects: 137
Study 28498504 — intervention group
Group type: COMPARATOR
Intervention: NRT (21 mg/day decreasing to 7 mg/day)
Number of subjects: 137
Study 28498504 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 137
Study 28498504 — intervention group
Group type: COMPARATOR
Intervention: NRT
Number of subjects: 137
Study 26342874 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous organogel materials coupled with liquid chromatography-tandem mass spectrometry (LC-MS-MS) for BPA extraction
Number of subjects: 0
Study 26342874 — intervention group
Group type: EXPERIMENTAL
Intervention: Porous organogel materials
Number of subjects: 0
Study 22788525 — intervention group
Group type: EXPERIMENTAL
Intervention: Avanafil 50 mg
Number of subjects: 83
Study 22788525 — intervention group
Group type: EXPERIMENTAL
Intervention: Avanafil 100 mg
Number of subjects: 83
Study 22788525 — intervention group
Group type: EXPERIMENTAL
Intervention: Avanafil 200 mg
Number of subjects: 83
Study 22788525 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil 50 mg
Number of subjects: 83
Study 22788525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 20652250 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐V Impulse (AVI) system
Number of subjects: 80
Study 20652250 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care with low molecular weight heparin)
Number of subjects: 80
Study 20652250 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 19249419 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide-containing anesthetic
Number of subjects: 7000
Study 19249419 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide-free anesthetic
Number of subjects: 7000
Study 16453953 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 component acellular pertussis vaccine (GlaxoSmithKline)
Number of subjects: 2781
Study 16453953 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A vaccine (Havrix) as a placebo
Number of subjects: 2781
Study 16194997 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental arithmetic
Number of subjects: 62
Study 16194997 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental arithmetic combined with exercise
Number of subjects: 62
Study 16194997 — intervention group
Group type: COMPARATOR
Intervention: Competitive exercise
Number of subjects: 62
Study 16194997 — intervention group
Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 62
Study 16194997 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise tasks
Number of subjects: 62
Study 12958109 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral morphine (sustained release)
Number of subjects: 48
Study 12958109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 9917047 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal spray, 100 microg/day for 4 to 6 weeks
Number of subjects: 21
Study 9917047 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroid exposure)
Number of subjects: 21
Study 7561986 — intervention group
Group type: EXPERIMENTAL
Intervention: Latex particle agglutination test (LPAT) for N. meningitidis C
Number of subjects: 299
Study 7561986 — intervention group
Group type: EXPERIMENTAL
Intervention: Latex particle agglutination test (LPAT) for H. influenzae type b
Number of subjects: 299
Study 7561986 — intervention group
Group type: EXPERIMENTAL
Intervention: Latex particle agglutination test (LPAT) for S. pneumoniae
Number of subjects: 299
Study 7561986 — intervention group
Group type: EXPERIMENTAL
Intervention: Latex particle agglutination test (LPAT) for all three organisms
Number of subjects: 299
Study 7561986 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive predictive value for children < 5 years
Number of subjects: 299
Study 7561986 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttest probability for children < 5 years
Number of subjects: 299
Study 7561986 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive predictive value for children < 14 years
Number of subjects: 299
Study 7561986 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttest probability for children < 14 years
Number of subjects: 299
Study 2197376 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol-LA, 80-mg tablets
Number of subjects: 42
Study 2197376 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol, 50-mg tablets
Number of subjects: 42
Study 2197376 — intervention group
Group type: COMPARATOR
Intervention: Control (no beta blocker therapy)
Number of subjects: 42
Study 6995615 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback training
Number of subjects: 31
Study 6995615 — intervention group
Group type: COMPARATOR
Intervention: Pseudotherapy
Number of subjects: 31
Study 6995615 — intervention group
Group type: COMPARATOR
Intervention: Symptom-monitoring control group
Number of subjects: 31
Study 12166539 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 56 microg b.i.d.
Number of subjects: 395
Study 12166539 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 200 microg b.i.d.
Number of subjects: 395
Study 12166539 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) 500 microg b.i.d.
Number of subjects: 395
Study 12166539 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 168 microg b.i.d.
Number of subjects: 395
Study 12166539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study 12166539 — intervention group
Group type: EXPERIMENTAL
Intervention: All active treatments (MF and BDP)
Number of subjects: 395
Study 12166539 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatments (MF and BDP)
Number of subjects: 395
Study 29342865 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown seaweed extract
Number of subjects: 60
Study 29342865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 27514714 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep intervention
Number of subjects: 802
Study 27514714 — intervention group
Group type: EXPERIMENTAL
Intervention: FAB intervention
Number of subjects: 802
Study 27514714 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination intervention
Number of subjects: 802
Study 27514714 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 802
Study 24676204 — intervention group
Group type: EXPERIMENTAL
Intervention: Live Attenuated Influenza Vaccine (LAIV)
Number of subjects: 0
Study 24676204 — intervention group
Group type: COMPARATOR
Intervention: Inactivated Influenza Vaccine (IIV)
Number of subjects: 0
Study 22341282 — intervention group
Group type: EXPERIMENTAL
Intervention: Web based interview process via Skype
Number of subjects: 39
Study 22341282 — intervention group
Group type: COMPARATOR
Intervention: Traditional on‐site interview process
Number of subjects: 39
Study 20332352 — intervention group
Group type: EXPERIMENTAL
Intervention: bromocriptine-QR
Number of subjects: 3095
Study 20332352 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3095
Study 18606284 — intervention group
Group type: EXPERIMENTAL
Intervention: Deployment of six speed cameras along an 8-mile corridor
Number of subjects: 0
Study 18606284 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed cameras
Number of subjects: 0
Study 18606284 — intervention group
Group type: EXPERIMENTAL
Intervention: Public opinion surveys
Number of subjects: 0
Study 16110283 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 45
Study 16110283 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Number of subjects: 45
Study 16110283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 12182275 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy
Number of subjects: 0
Study 12182275 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 10839650 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic progesterone (EP)
Number of subjects: 54
Study 10839650 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen alone (ES)
Number of subjects: 54
Study 10839650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 7502281 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade cardioplegia
Number of subjects: 21
Study 7502281 — intervention group
Group type: COMPARATOR
Intervention: Retrograde cardioplegia
Number of subjects: 21
Study 7502281 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study 2310576 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% oxymetazoline
Number of subjects: 42
Study 2310576 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% cocaine
Number of subjects: 42
Study 2310576 — intervention group
Group type: COMPARATOR
Intervention: 4% lidocaine with 1:100,000 epinephrine
Number of subjects: 42
Study 7002568 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 80-160 mg t.i.d. for 10 days
Number of subjects: 12
Study 30477816 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (low-Cd rice)
Number of subjects: 106
Study 30477816 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group (high-Cd rice)
Number of subjects: 106
Study 30477816 — intervention group
Group type: COMPARATOR
Intervention: Control group (low-Cd rice)
Number of subjects: 106
Study 29197412 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward group (n = 37) using performance feedback and contingent monetary reward
Number of subjects: 74
Study 29197412 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 37) using the same system but without monetary reward and with reduced performance feedback
Number of subjects: 74
Study 25739726 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 46
Study 25739726 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 46
Study 23770377 — intervention group
Group type: COMPARATOR
Intervention: Almorexant 100mg in subjects with mild liver impairment (Group A)
Number of subjects: 35
Study 23770377 — intervention group
Group type: COMPARATOR
Intervention: Almorexant 100mg in subjects with moderate liver impairment (Group B)
Number of subjects: 35
Study 21632265 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol infusion
Number of subjects: 260
Study 21632265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 19220277 — intervention group
Group type: EXPERIMENTAL
Intervention: Microemulsion propofol
Number of subjects: 147
Study 19220277 — intervention group
Group type: COMPARATOR
Intervention: Lipid emulsion propofol
Number of subjects: 147
Study 19220277 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% PEG660 HS
Number of subjects: 147
Study 16699123 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Life Skills Training (LST)
Number of subjects: 0
Study 16699123 — intervention group
Group type: EXPERIMENTAL
Intervention: Infused Life Skills Training (LST) delivery method
Number of subjects: 0
Study 14660159 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral medication adherence on drug use days
Number of subjects: 12
Study 14660159 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral medication adherence on matched abstinence days
Number of subjects: 12
Study 10719624 — intervention group
Group type: EXPERIMENTAL
Intervention: Spleen peptide preparation (Polyerga) during chemotherapy (cisplatin/carboplatin, 5‐fluorouracil)
Number of subjects: 40
Study 8842556 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone for 7 days
Number of subjects: 19
Study 8842556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 1847239 — intervention group
Group type: EXPERIMENTAL
Intervention: CT imaging
Number of subjects: 170
Study 1847239 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 170
Study 6884410 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10
Study 6884410 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol glucuronide
Number of subjects: 10
Study 6884410 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hydroxypropranolol
Number of subjects: 10
Study 6884410 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hydroxypropranolol glucuronide
Number of subjects: 10
Study 6884410 — intervention group
Group type: EXPERIMENTAL
Intervention: Naphthoxylactic acid
Number of subjects: 10
Study 6884410 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol binding in cord plasma
Number of subjects: 10
Study 6884410 — intervention group
Group type: EXPERIMENTAL
Intervention: Naphthoxylactic acid binding in cord plasma
Number of subjects: 10
Study 31177631 — intervention group
Group type: EXPERIMENTAL
Intervention: M-SAKHI intervention delivered by ASHAs
Number of subjects: 2501
Study 31177631 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2501
Study 31177631 — intervention group
Group type: EXPERIMENTAL
Intervention: M-SAKHI intervention
Number of subjects: 2501
Study 28338706 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h urine samples
Number of subjects: 1000
Study 28338706 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot urine samples using Tanaka equation
Number of subjects: 1000
Study 28338706 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot urine samples using Kawasaki equation
Number of subjects: 1000
Study 28338706 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot urine samples using Mage equation
Number of subjects: 1000
Study 28338706 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot urine samples using Toft equation
Number of subjects: 1000
Study 28338706 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot urine samples using INTERSALT equation
Number of subjects: 1000
Study 28338706 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot urine samples using INTERSALT equation with potassium
Number of subjects: 1000
Study 26087958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/rosuvastatin 10 mg
Number of subjects: 43
Study 26087958 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 20 mg
Number of subjects: 43
Study 23548674 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux dialysis
Number of subjects: 618
Study 23548674 — intervention group
Group type: COMPARATOR
Intervention: Low-flux dialysis
Number of subjects: 618
Study 23548674 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cardiovascular disease and NT-proBNP above median
Number of subjects: 618
Study 21817939 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone‐Anchored Hearing Aid surgery without skin thinning (test group)
Number of subjects: 18
Study 21817939 — intervention group
Group type: COMPARATOR
Intervention: Traditional Bone‐Anchored Hearing Aid procedure (control group)
Number of subjects: 18